PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of oncotargetLink to Publisher's site
 
Oncotarget. 2016 November 22; 7(47): 76944–76954.
Published online 2016 October 19. doi:  10.18632/oncotarget.12759
PMCID: PMC5363561

Elevation of n-3/n-6 PUFAs ratio suppresses mTORC1 and prevents colorectal carcinogenesis associated with APC mutation

Abstract

Although epidemiological and preclinical studies have shown the preventative effect of n-3 polyunsaturated fatty acids (PUFAs) on colorectal cancer (CRC), the underlying molecular mechanisms are not clear. In this study, we revealed that elevation of n−3/n-6 PUFAs ratio suppress the mechanistic target of rapamycin complex 1 (mTORC1) and prevent colorectal tumorigenesis. The transgenic expression of fat-1, a desaturase that catalyzes the conversion of n-6 to n-3 PUFAs and produces n-3 PUFAs endogenously, repressed colorectal tumor cell growth and remarkably reduced tumor burden, and alleviated anemia as well as hyperlipidemia in APCMin/+ (adenomatous polyposis coli) mice, a classic CRC model that best simulates most clinical cases. In contrast to arachidonic acid (AA, C20:4 n−6), either Docosahexaenoic acid (DHA, C22:6 n−3), eicosapentaenoic acid (EPA, C20:5 n−3), or a combination of DHA and AA, efficiently inhibited the proliferation of CRC cell lines and promoted apoptosis in these cells. The ectopic expression of fat-1 had similar effects in colon epithelial cells with APC depletion. Mechanistically, elevation of n−3/n−6 ratio suppressed mTORC1 activity in tumors of APCMin/+ mice, CRC cell lines with APC mutation, and in normal colon epithelial cells with APC depletion. In addition, elevation of n−3/n−6 ratio repressed mTORC1 activity and inhibited adipogenic differentiation in preadipocytes with APC knockdown, as well as alleviated hyperlipidemia in APCMin/+ mice. Taken together, our findings have provided novel insights into the potential mechanism by which increase in n−3/n−6 PUFAs ratio represses CRC development, and also a new rationale for utilizing n-3 PUFAs in CRC prevention and treatment.

Keywords: PUFA, mTOR complex 1, colorectal cancer, APC

INTRODUCTION

Colorectal cancer (CRC) ranks the second most prevalent cancer among women and the third among men worldwide [1]. Crucial risk factors have been identified by epidemiological studies, including but not limited to the imbalanced dietary intake of fatty acids, high concentration of serum triglycerides and cholesterol, and mutations in key tumor suppressor genes such as adenomatous polyposis coli (APC). Notably, since APC is an endogenous inhibitor of tumorigenic β-catenin, the APC mutation leads to β-catenin stabilization, constitutive activation of Wnt signaling, and the consequent familial adenomatous polyposis (FAP) and sporadic colorectal cancer [25]. As attractive candidate ‘natural’ CRC chemoprevention agents, n-3 polyunsaturated fatty acids (PUFAs) have demonstrated beneficial effects in the prevention of CRC in both humans and mice. A case control study of 1872 patients demonstrated a significant dose-dependent reduction in CRC risk for total n-3 PUFAs intake, as well as for EPA and DHA intake individually [6]. Moreover, a Phase III double-blind randomized clinical trial with EPA for 6 months on rectal polyps in patients with FAP provided the first definitive evidence of chemopreventive efficacy of EPA in humans with a marked decrease in adenoma numbers and a cumulative reduction in adenoma size [7]. Consistently, rodents fed n-3 PUFAs versus n−6 PUFAs or low-fat control diet controls showed a 20–50% reduction in tumor incidence induced by both APC mutation and carcinogens [8]. However, the underlying mechanisms associated with this effect remain unclear.

Mechanistic target of rapamycin (mTOR) is a highly conserved Ser/Thr kinase that integrates diverse components, including nutrients, growth factors, energy, and stresses, to control cell growth, proliferation, survival and metabolism [913]. mTOR elicits its pleiotropic functions via two functionally distinct signaling complexes known as mTOR complex 1 (mTORC1) and complex 2 (mTORC2). mTORC1 plays a key role in translation initiation by directly phosphorylating p70 S6 kinase 1 (S6K1) and 4E-BP1. Recent evidence indicates that mTORC1 signaling is a key event in promoting the development of colorectal cancer, and the activation of the mTORC1 signaling pathway is observed in up to 40% cases of colorectal tumor [1318]. Considering that mTORC1 promotes adipocyte differentiation [19] as well as lipid uptake and synthesis in adipose tissue [20], and considering our previous study on the targeting of mTORC1 by n−3 PUFAs in breast cancer [21], we hypothesize that n−3 PUFAs suppress mTORC1 activity and thereby prevent CRC and associated hyperlipidemia.

Because the amount, source, and ratio of PUFAs vary widely and lead to inconsistent results, a transgenic mouse model that expresses fat-1, an n−3 fatty acid desaturase, was developed [22]. Since this enzyme can catalyze the conversion of n-6 PUFAs to n−3 PUFAs by introducing a double bond into fatty acyl chains, the fat-1 transgenic mice will enable the investigation of the biological properties of n-3 PUFAs without having to incorporate n−3 PUFAs in the diet, and this strategy represents a more reliable and intuitive model [23]. Since mutations in the gene coding for APC account for most clinical cases of familial adenomatous polyposis (FAP) and sporadic colonic tumors [5], C57BL/6J-APCMin/+ mouse strains have been established to simulate CRC associated with APC mutation, with multiple intestinal adenomas and complications that resemble clinical CRC cases, including anemia and rectal prolapse [24, 25].

In this study, for the first time we crossed fat-1 transgenic mice with APCMin/+ mice and generated a novel mouse strain, fat-1-APCMin/+ double-hybrid, to investigate the preventive effects of elevation of n–3/n–6 ratio on CRC associated with APC mutation and the underlying mechanisms. Elevated n−3/n−6 ratio suppressed the activity of mTORC1 in vitro and in vivo, prevented colorectal carcinogenesis and tumor growth, and alleviated associated anemia and rectal relapse. Taken together, our results provide a new rationale and exciting therapeutic value of utilizing n–3 PUFAs to target CRC and associated anemia, particularly in cases involving APC mutation.

RESULTS

fat-1- APCMin/+ mice demonstrate marked suppression of colorectal tumorigenesis and accompanying anemia compared with APCMin/+ mice

The fat-1 transgenic mice were crossed with the APCMin/+ mice to create a novel double-hybrid mice model with the view to provide a purely genetic approach to investigate the effects of elevation of n−3/n−6 PUFA ratio on colorectal tumorigenesis. The generation of fat-1-APCMin/+ mice was not only verified through genotyping (Supplementary Figure S1) but also confirmed by examining the relative content of n-6 and n-3 PUFAs in the tails (Supplementary Table S1) as well as in mucosal tissues (Supplementary Table S2). In both tissue samples of the fat-1-APCMin/+ mice there was a significant elevation of n-3/n-6 PUFAs ratio compared with that of APCMin/+ control mice. As expected, the number of tumors palpated in fat-1-APCMin/+ mice, whether in the small intestine or colon, was significantly lower (P < 0.05) than that in APCMin/+ control mice (Figure 1A–1C). In addition, the volume of the tumors in fat-1-APCMin/+ mice was much smaller than that in the APCMin/+ mice (Figure (Figure1C1C and and1D),1D), and anemia, one of the most common complications in clinical cases of CRC in APCMin/+ mice [2628], was significantly mitigated in fat-1-APCMin/+ mice, on the basis of the spleen weight and hemoglobin level (Figure 2A–2C). Moreover, rectal prolapse, another complication of CRC, was completely prevented in fat-1-APCMin/+ mice (Figure (Figure2D2D)

Figure 1
Fat-1-APCMin/+ mice manifest a clear reduction in the number and size of adenomas compared with APCMin/+ mice
Figure 2
Anemia is ameliorated and rectal prolapse is prevented in fat-1-APCMin/+ mice compared with APCMin/+ mice

Endogenous production or exogenous delivery of n-3 PUFAs suppresses the proliferation and promotes apoptosis in CRC cell lines and normal colon epithelia with APC depletion

To investigate the potential protective role of increasing n-3/n-6 ratio against CRC associated with APC mutation in vitro, we examined the effect of Docosahexaenoic acid (DHA, C22:6 n−3), eicosapentaenoic acid (EPA, C20:5 n-3), arachidonic acid (AA, C20:4 n−6), or a combination of both DHA or AA, on the proliferation of SW480, a CRC cell line with truncated APC and consequently with constitutively active β-catenin-TCF-regulated transcription (CRT, the best established hallmark of activated Wnt signaling), and on the proliferation of HCT116 cells, a CRC cell line with a β-catenin mutation that also leads to constitutively active CRT [29]. As expected, DHA or EPA dose-dependently inhibited cell proliferation in these cells (Figure (Figure3A3A and and3B),3B), which is consistent with our previous results in breast cancer cells [21]. Additionally, CRC cell proliferation promoted by AA was successfully inhibited by simultaneous treatment with DHA, in a dose-dependent manner (Figure (Figure3A).3A). Furthermore, we transfected NCM460 cells with the APC siRNA (designated NCM460-siAPCs), because the loss of function of APC may be a crucial event in the early transformation of colonic epithelium [30], to interrogate the effect of increased n−3/n−6 ratio on the early transformed colonic epithelium. In consistence, the ectopic expression of fat-1 in NCM460-siAPCs also resulted in a significant elevation of n−3/n−6 ratio in these cells (Supplementary Table S3) suppressed their proliferation (Figure (Figure3C3C left).

Figure 3
DHA and endogenous n-3 PUFAs repress the proliferation of colorectal tumor cells

As expected, APC was sufficiently depleted, which leads to β-catenin stabilization (Figure (Figure3C3C right).

Furthermore, studies have shown that n−3 PUFAs promote apoptosis in a variety of cancer cells [31]. We next examined whether n-3 PUFAs potentiate cellular apoptosis in CRC in vitro. DHA dose-dependently increased the number of dead cells in serum-starved HCT116, SW480, and NCM460-siAPC cell lines (Figure 4A, 4C, and and4E).4E). The cleavage of poly (ADP-ribose) polymerase (PARP) by active caspase-3—widely accepted as a hallmark of late-stage apoptosis but not necrosis—was consistently enhanced by DHA in a dose-dependent manner (Figure 4B, 4D, and and4F).4F). Moreover, while AA alone had little effect, both DHA, EPA and a combination of DHA and AA markedly increased apoptosis of SW480 cells under serum starvation, as shown by Annexin V-FITC assay (Supplementary Figure S2A and S2B).

Figure 4
DHA promotes colorectal tumor cell apoptosis in vitro

Endogenous production or exogenous delivery of n-3 PUFAs inhibit mTORC1 activity in APCMin/+ mice, CRC cell lines, and NCM460-siAPC cells

Recent studies have revealed the critical role of mTORC1 activity in the proliferation and survival of CRC cells. Interestingly, our previous results demonstrated that arachidonic acid (AA), an n−6 PUFA, induced mTORC1 activity and promoted breast carcinogenesis and angiogenesis [32]. The opposite effects of n-3 and n-6 PUFAs in CRC prompted us to examine whether n-3 PUFAs negatively regulate mTORC1 signaling and consequently inhibit the proliferation and survival of CRC cells. Consistent with our hypothesis, the phosphorylation at S235/236 of S6 (the best characterized indicator of mTORC1 activation) was reduced in the tumors of fat-1-APCMin/+ mice compared with those of APCMin/+ control mice (Figure (Figure5A).5A). DHA rapidly suppressed the levels of insulin and amino acid-stimulated phosphorylation of S6 in a dose-dependent manner (S235/236) in HCT116 cells (Figure 5B–5E). Consistently, DHA or EPA significantly reduced phosphorylation of p70S6K1 (T389, another key hallmark of mTORC1 activation) induced by insulin and (or) AA treatment in SW480 cells under serum starvation (Supplementary Figure S3A), and to a lesser extent, under normal growth conditions (Supplementary Figure S3B). We next examined the effect of endogenously produced n−3 PUFAs on mTORC1 signaling. In NCM460-siAPCs, fat-1 overexpression significantly reduced the phosphorylation of S6 (S235/235) compared with the cells transfected with the control vector (Figure (Figure5F5F).

Figure 5
n-3 PUFAs inhibit mTORC1 signaling in vivo and in vitro

Inhibition of mTORC1 phenocopies the effects of n-3 PUFAs on proliferation and apoptosis of CRC cells

To interrogate whether the effects of n-3 on proliferation and apoptosis of CRC cells are through mTORC1, SW480 cells treated with rapamycin, a specific mTORC1 inhibitor, were analyzed for proliferation or viability, respectively. As expected, rapamycin treatment suppressed proliferation of SW480 cells (Figure (Figure6A)6A) and enhanced their death (Figure (Figure6B),6B), phenocopying that of n-3 PUFAs and suggesting n−3 PUFAs' effects on CRC cells are via mTORC1, at least partially.

Figure 6
Inhibition of mTORC1 signaling in CRC cells has growth inhibitory and apoptotic effects similar to n-3 PUFAs

Ectopic expression of fat-1 reduces mTORC1 activity and suppresses adipogenic differentiation in preadipocytes with silenced APC, and fat-1 transgenic APCMin/+ mice have lower serum lipid levels

Accompanying the markedly reduced mTORC1 activity, fat-1-APCMin/+ mice demonstrated significantly decreased serum lipid levels compared with APCMin/+ mice (Figure 7A–7D). Since mTORC1 activity is critical for the terminal differentiation of 3T3-L1 preadipocytes [19], we analyzed the effects of ectopic fat-1 expression or DHA treatment on mTORC1 activity and adipogenic differentiation in 3T3-L1 with previous depletion of the APC gene. As expected, APC depletion triggered a marked induction of both mTORC1 activity (based on the observation of the phosphorylation of S6), which was considerably reversed by either overexpression of fat-1 (Figure (Figure7E)7E) or DHA treatment (Figure (Figure7F).7F). Consistently, adipogenic differentiation induced by APC depletion in 3T3-L1 preadipocytes was markedly reversed by DHA treatment (Figure (Figure7G7G and and7H).7H). Collectively, these results suggest that the cellular productions of n-3 PUFAs and lowered n−6/n−3 ratio effectively alleviates hyperlipidemia, which is closely correlated with CRC associated with APC mutation, possibly via suppression of mTORC1 activity in adipogenesis.

Figure 7
n-3 PUFAs inhibit serum lipids in APCMin/+ mice and suppress differentiation preadipocytes with silenced APC

DISCUSSION

Previous studies have found that n−3 PUFAs are beneficial for the prevention and treatment of CRC [8]. However, the mechanisms underlying n-3 PUFAs' effects on CRC, especially CRC due to APC mutations, which occur in most clinical cases, remain largely unknown. Due to inconsistent results brought by the varieties of PUFAs, we crossed fat-1 mice, which convert n−6 PUFAs to n−3 PUFAs endogenously, with APCMin/+ mice, generating a novel fat-1-APCMin/+ double transgenic mice model to study the effects of endogenous n−3 PUFAs on colorectal carcinogenesis associated with APC mutation. In addition, to simulate tumor development of colorectal cancer associated with APC mutation and determine the inhibitory effect of n-3 PUFAs in vitro, we constructed a new study model by transfecting the normal colon cell line NCM460 with APC siRNA. The combined results from fat-1-APCMin/+ mice, CRC cell lines (SW480 and HCT116), and NCM460 cells with silenced APC revealed that elevated n−3/n−6 PUFAs ratio through either intracellular conversion of n−6 to n−3, or through n−3 supplementation, can significantly repress the proliferation and promote apoptosis in colorectal cancer cells, and inhibit the formation of intestinal adenomas, thereby preventing the development of colorectal cancer, as well as the accompanying anemia.

It is remarkable that the mTORC1 activity in the tumors of fat-1-APCMin/+ double-hybrid mice significantly decreased compared with APCMin/+ mice. Accordingly, DHA or EPA treatment inhibited the mTORC1 activity in the CRC cell lines. Moreover, the ectopic expression of fat-1 suppressed the mTORC1 activity in NCM460 cells transformed by APC depletion. Conversely, treatment of CRC cells with rapamycin, an mTORC1 specific inhibitor, demonstrated growth inhibitory and proapoptotic effects similar to n-3 PUFAs. Taken together, these results suggest that mTORC1 inhibition may be correlated with the effects of increased n-3/n-6 ratio on CRC associated with APC mutation. How increased n−3/n−6 ratio suppresses mTORC1 activity needs further investigation, although recent data indicates DHA and EPA increase pTEN expression in breast cancer cells [33], which may in turn suppress pI-3k/Akt and subsequently repress the activation of mTORC1.

Numerous epidemiological studies have suggested that the level of serum lipids is strongly correlated with CRC [3436]. Consistently, APCMin/+ mice, a classic and widely recognized mouse model of CRC, also suffer severe hyperlipidemia. However, the role of serum lipids in CRC remains unclear. Interestingly, the fat-1-APCMin/+ double transgenic mice demonstrated significantly decreased serum lipid levels. Because recent evidence suggests that the mTORC1 plays a critical role in PPARγ-mediated adipogenesis [19], fat accretion, and lipemia [20], n−3/n−6 ratio elevated intrinsically in fat-1-APCMin/+ mice might lower serum lipids via suppression of mTORC1. In this context, the fact that enforced expression of fat-1 in 3T3-L1 preadipocytes restored the mTORC1 activity elevated by APC depletion and that DHA treatment inhibited adipogenic differentiation of 3T3-L1 preadipocytes potentiated by APC depletion, collectively suggesting a possible role of increasing n-3/n-6 ratio in the suppression of mTORC1 activation induced by APC depletion and the consequent adipogenesis and lipemia.

In conclusion, using both transgenic mice and cellular models, we have shown that (1) stable elevation of n−3/n−6 ratio via transgenic expression of fat-1 prevent colorectal carcinogenesis associated with APC mutation and alleviate the accompanying anemia and rectal relapse; (2) the inhibition of mTORC1 by increased n−3/n−6 ratio is associated both with the suppression of CRC development itself and with the rebalance of lipid metabolism associated with CRC. These findings provide novel mechanistic insights into the suppressive effects of n-3 PUFAs on CRC and may shed light on the prevention and non-invasive treatment of CRC as well as its associated complications.

MATERIALS AND METHODS

Materials

All cell culture reagents were obtained from Gibco BRL Technology (Gaithersburg, MD, USA). Arachidonic acid and DHA were obtained from Cayman Chemical (Ann Arbor, Michigan, USA). Insulin, antibodies against β-actin, and HRP-conjugated anti-mouse and anti-rabbit IgG antibodies were purchased from Sigma (St Louis, MO, USA). Primary antibodies against phospho-S6 (S235/236) and PARP were obtained from Cell Signaling Technology (Danvers, MA, USA). S6, fat-1, phospho-Akt (S473), and Akt antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Recombinant adenovirus with or without the fat-1 gene was produced by cloning fat-1 cDNA into the RAPAd CMV using the Adenoviral Expression System (Cell Biolabs) (San Diego, CA, USA).

Cell culture

Cell lines HCT116, SW480, SW620, NCM460, and 3T3-L1 were obtained from ATCC. Cell lines were frozen in bulk upon receipt and were maintained in RMPI-1640 (NCM460), Leibovitz' L-15 (SW480 and SW620), or Dulbecco's modified Eagle's medium (HCT116 and 3T3-L1) supplemented with 10% fetal bovine serum at 37°C, 5% CO2, and 95% humidity.

Cell proliferation assay

Cells (104/well) were plated in 96-well plates in complete medium. After 24 h, serial concentrations of DHA (10–150 μM) were added to the medium for 72 h, with the replacement of DHA every 24 h. Cell viability was assessed using the Cell Counting Kit-8 (WST-8) (Dojindo Molecular Technologies Inc., Kumamoto, Japan), following the manufacturer's instructions. NCM460 cells were transfected with the pST180-fat-1 vector or with the control vector. After 48 h, cell viability was assessed as described above.

Assessment of cell death and apoptosis

After 24 h of adhesion, cells were serum-starved and cultured for 8 or 12 h in the presence or absence of serial concentrations of DHA (dissolved in basic medium). Proteins were extracted for the immunoblot analysis of cleaved-PARP. Cells from the 12-h group were trypsinized to make a single cell suspension. A 10-μL volume of 0.4% trypan blue dye was added to a 10-μL volume of cell suspension, and cell death was quantified using a TC10™ Automated Cell Counter (Bio-Rad) according to the manufacturer's instructions. Data from three repeat counts were averaged. Apoptotic cells were also detected with the Annexin V-FITC double-staining kit (BD Pharmingen). For analysis of the apoptotic populations of SW480 cells, both early and late apoptotic cells were scored.

siRNAs and plasmids transfection

Plated NCM460 and 3T3-L1 cells were transfected with APC siRNA or pST180-fat-1 vector (see Table for sequences) using Lipofectamine 2000 (Life technologies) according to the manufacturer's instructions. After 48 h, proteins were extracted for western blot analysis.

Mouse breeding

APCMin/+ mice (Jax Number: 002020) (C57BL/6 substrain) were bred with fat-1 transgenic mice (C57BL/6 substrain) to generate fat-1- APCMin/+ double-hybrid mice. Littermates that lacked the fat-1 transgenic gene were used as controls. DNA extracted from the tails of the offspring were subjected to PCR for genotyping in accordance with the protocol described on the Jackson Laboratory webpage and using primers listed in the Supplementary Method. At 24 weeks of age, the mice were killed by cervical dislocation.

Tissue harvesting and tumor analysis

Body weight was monitored weekly. After 24 weeks, mice were sacrificed by cervical dislocation under anesthesia with isofluorane (IsoFlo, Burns Vet Supply) and blood samples were collected by intracardiac puncture and immediately stored at −80°C. The entire gastrointestinal tract was immediately removed, washed with phosphate buffered saline (PBS), and divided into four segments [I– III from proximal small intestine (I) to distal small intestine (III), and colon]. The intestines were then spread flat between sheets of filter paper and fixed in buffered 10% formalin for at least 48 h. The number, location, and size of visible tumors were determined at a 10× magnification using an Olympus SZXILLB100 microscope by two independent investigators blinded to the results. Polyps throughout the intestinal tract were classified into four categories (< 1 mm, 1–2 mm, 2–3 mm, and > 3 mm).

Statistical analysis

Data are presented as mean ± SEM of at least three independent experiments. Differences between groups were analyzed using Student's t-test or one-way ANOVA (SPSS version 13.0), and a level of p < 0.05 was considered statistically significant. All the experiments including Western Blotting were performed at least three times with similar results.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES

Abbreviations

AA
arachidonic acid
APC
adenomatous polyposis coli
CRC
colorectal cancer
DHA
Docosahexaenoic acid
EPA
eicosapentaenoic acid
FAP
familial adenomatous polyposis
mTORC1
mechanistic target of rapamycin complex 1
PUFAs
polyunsaturated fatty acids.

Footnotes

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

FUNDING

We acknowledge funding from the State Key Development Program for Basic Research of China (2013CB945203, 2015CB55360), National Natural Sciences Foundation of China (U1301222, 81530070, 81301525 and 81372136), and Natural Science Foundation of Guangdong Province (2015A030313270).

Contributed by

Authors' contributions

Z.H., Z.Z., and S.Y. designed research; L.M., Z.L., Z.B., H.M., D.X., and L.X. performed experiments; D.Y., Z.Z., and B.X. contributed to data analysis; Z.Z. and Z.H. wrote the paper; Z.H., Z.Z. and B.X. contributed to study supervision.

REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. [PubMed]
2. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;21:2525–2538. [PubMed]
3. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature. 1992;359:235–237. [PubMed]
4. Peters U, Bien S, Zubair N. Genetic architecture of colorectal cancer. Gut. 2015;64:1623–1636. [PMC free article] [PubMed]
5. Nathke IS. The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. Annu Rev Cell Dev Biol. 2004;20:337–366. [PubMed]
6. Kim S, Sandler DP, Galanko J, Martin C, Sandler RS. Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans. Am J Epidemiol. 2010;171:969–979. [PMC free article] [PubMed]
7. West NJ, Clark SK, Phillips RK, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut. 2010;59:918–925. [PubMed]
8. Cockbain AJ, Toogood GJ, Hull MA. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut. 2012;61:135–149. [PubMed]
9. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484. [PubMed]
10. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293. [PMC free article] [PubMed]
11. Bai X, Jiang Y. Key factors in mTOR regulation. Cellular and molecular life sciences. 2010;67:239–253. [PMC free article] [PubMed]
12. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122:3589–3594. [PubMed]
13. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35. [PMC free article] [PubMed]
14. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene. 2006;25:6436–6446. [PubMed]
15. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010;22:169–176. [PMC free article] [PubMed]
16. Fujishita T, Aoki M, Taketo MM. The role of mTORC1 pathway in intestinal tumorigenesis. Cell cycle. 2009;8:3684–3687. [PubMed]
17. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL, Evers BM. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 2010;210:767–776. 776–768. [PMC free article] [PubMed]
18. Nozawa H, Watanabe T, Nagawa H. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett. 2007;251:105–113. [PubMed]
19. Kim JE, Chen J. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004;53:2748–2756. [PubMed]
20. Blanchard PG, Festuccia WT, Houde VP, St-Pierre P, Brule S, Turcotte V, Cote M, Bellmann K, Marette A, Deshaies Y. Major involvement of mTOR in the PPARgamma-induced stimulation of adipose tissue lipid uptake and fat accretion. J Lipid Res. 2012;53:1117–1125. [PMC free article] [PubMed]
21. Chen Z, Zhang Y, Jia C, Wang Y, Lai P, Zhou X, Wang Y, Song Q, Lin J, Ren Z, Gao Q, Zhao Z, Zheng H, et al. mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression. Oncogene. 2014;33:4548–4557. [PubMed]
22. Wei D, Li J, Shen M, Jia W, Chen N, Chen T, Su D, Tian H, Zheng S, Dai Y, Zhao A. Cellular production of n-3 PUFAs and reduction of n-6-to-n-3 ratios in the pancreatic beta-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death. Diabetes. 2010;59:471–478. [PMC free article] [PubMed]
23. Kang JX. A transgenic mouse model for gene-nutrient interactions. J Nutrigenet Nutrigenomics. 2008;1:172–177. [PubMed]
24. Moser AR, Dove WF, Roth KA, Gordon JI. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol. 1992;116:1517–1526. [PMC free article] [PubMed]
25. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990;247:322–324. [PubMed]
26. Sadahiro S, Suzuki T, Tokunaga N, Mukai M, Tajima T, Makuuchi H, Saito T. Anemia in patients with colorectal cancer. J Gastroenterol. 1998;33:488–494. [PubMed]
27. Munoz M, Gomez-Ramirez S, Martin-Montanez E, Auerbach M. Perioperative anemia management in colorectal cancer patients: a pragmatic approach. World J Gastroenterol. 2014;20:1972–1985. [PMC free article] [PubMed]
28. Kallianpur AA, Muduly D, Shukla NK, Deo SV, Yadav R, Pandit A. Synchronous colorectal cancer with aplastic anemia. Trop Gastroenterol. 2013;34:41–43. [PubMed]
29. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787–1790. [PubMed]
30. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC−/− colon carcinoma. Science. 1997;275:1784–1787. [PubMed]
31. Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett. 2008;269:363–377. [PMC free article] [PubMed]
32. Wen ZH, Su YC, Lai PL, Zhang Y, Xu YF, Zhao A, Yao GY, Jia CH, Lin J, Xu S, Wang L, Wang XK, Liu AL, et al. Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis. Oncogene. 2013;32:160–170. [PubMed]
33. Ghosh-Choudhury T, Mandal CC, Woodruff K, St Clair P, Fernandes G, Choudhury GG, Ghosh-Choudhury N. Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat. 2009;118:213–228. [PMC free article] [PubMed]
34. Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer causes & control. 2015;26:257–268. [PubMed]
35. Chung YW, Han DS, Park YK, Son BK, Paik CH, Lee HL, Jeon YC, Sohn JH. Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea. Dig Liver Dis. 2006;38:668–672. [PubMed]
36. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev. 1994;3:687–695. [PubMed]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC